187 related articles for article (PubMed ID: 26516697)
1. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
Calderaro J; Nault JC; Balabaud C; Couchy G; Saint-Paul MC; Azoulay D; Mehdaoui D; Luciani A; Zafrani ES; Bioulac-Sage P; Zucman-Rossi J
Mod Pathol; 2016 Jan; 29(1):43-50. PubMed ID: 26516697
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
[TBL] [Abstract][Full Text] [Related]
3. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract][Full Text] [Related]
4. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
[TBL] [Abstract][Full Text] [Related]
5. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.
Putra J; Ferrell LD; Gouw ASH; Paradis V; Rishi A; Sempoux C; Balabaud C; Thung SN; Bioulac-Sage P
Mod Pathol; 2020 Apr; 33(4):665-675. PubMed ID: 31570768
[TBL] [Abstract][Full Text] [Related]
6. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J
Nat Commun; 2013; 4():2218. PubMed ID: 23887712
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
Zucman-Rossi J; Jeannot E; Nhieu JT; Scoazec JY; Guettier C; Rebouissou S; Bacq Y; Leteurtre E; Paradis V; Michalak S; Wendum D; Chiche L; Fabre M; Mellottee L; Laurent C; Partensky C; Castaing D; Zafrani ES; Laurent-Puig P; Balabaud C; Bioulac-Sage P
Hepatology; 2006 Mar; 43(3):515-24. PubMed ID: 16496320
[TBL] [Abstract][Full Text] [Related]
8. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
[TBL] [Abstract][Full Text] [Related]
9. Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.
Hechtman JF; Abou-Alfa GK; Stadler ZK; Mandelker DL; Roehrl MHA; Zehir A; Vakiani E; Middha S; Klimstra DS; Shia J
Hum Pathol; 2019 Jan; 83():1-6. PubMed ID: 30121369
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Adenomas: Morphology and Genomics.
Bioulac-Sage P; Sempoux C; Balabaud C
Gastroenterol Clin North Am; 2017 Jun; 46(2):253-272. PubMed ID: 28506364
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
[TBL] [Abstract][Full Text] [Related]
13. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics.
Dhingra S; Fiel MI
Arch Pathol Lab Med; 2014 Aug; 138(8):1090-7. PubMed ID: 25076298
[TBL] [Abstract][Full Text] [Related]
14. New monoallelic (partial tandem duplication) mutation of HNF1a gene in steatotic hepatocellular adenoma.
Sakellariou S; Morgan Y; Heaton N; Portmann B; Quaglia A; Tobal K
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):623-7. PubMed ID: 21566527
[TBL] [Abstract][Full Text] [Related]
15. Subtype classification of hepatocellular adenoma.
Bioulac-Sage P; Balabaud C; Zucman-Rossi J
Dig Surg; 2010; 27(1):39-45. PubMed ID: 20357450
[TBL] [Abstract][Full Text] [Related]
16. Recurrent chromosomal rearrangements of
Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of hepatocellular adenoma in clinical practice.
Nault JC; Paradis V; Cherqui D; Vilgrain V; Zucman-Rossi J
J Hepatol; 2017 Nov; 67(5):1074-1083. PubMed ID: 28733222
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.
Pinyol R; Tovar V; Llovet JM
J Hepatol; 2014 Sep; 61(3):685-7. PubMed ID: 24859456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
